Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil for Calcinosis in Systemic Sclerosis
NCT02663895Phase 2Completed
- Sponsor
- Stanford University
- Start
- Oct 2016
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treprostinil in calcinosis, sponsored by Stanford University. Primary endpoints: Number of Participants With Treatment-related Adverse Events at 12 months and Median Rate of Change of Calcinosis in Radiograph at 12 months. Started Oct 2016; status: completed.
02
Drugs
treprostinil
03
Conditions
calcinosis
Beyond the preview
Go deeper on NCT02663895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663895.